In terms of the cardiac field, at the recent Society of Nuclear Medicine meeting, certainly there were comments made about how—at least in the cardiac imaging realm—we've been able to manage this both at the Ottawa Heart Institute but also nationally, in terms of being able to switch over to thallium. Many American centres haven't used thallium for a long time and they're looking to us for guidance in terms of how to make that switchover in their departments. So we've been an example that we should be proud of.
It's an example of how we as a community have been able to work together to try to solve some of these problems. Certainly, with Dr. McEwan's leadership, we look forward to solving a lot of these problems as we go forward. Nuclear medicine is certainly an important community, but there are also cardiology patients and oncology patients who are being affected. These specialties also need to be engaged in the process, and I'm pleased to hear that this will be happening.